The FDA has granted approval for Cosette’s Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.

Sanofi has signed a global licensing and strategic collaboration agreement with ScionxBio to develop long-acting mRNA therapies using the TERA platform.

Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.

UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare products Regulatory Agency (MHRA) said it would consider allowing ...

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.

Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases.

Revolution’s Rasonque has been called a turning point for pancreatic cancer patients, nearly doubling median overall survival in the second-line setting.

Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical ...

The US FDA has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of AD, including the clinical progression of its lead candidate, ...

The duo of funds will support companies across the biopharma, healthcare technology, diagnostics and medical device disciplines.